I Wish This Product Had Been Available When My Dad had Cancer...

Discussion in 'Health and medical' started by Myra Dwyer, Feb 1, 2004.

  1. Myra Dwyer

    Myra Dwyer Guest

    PRESS RELEASE:

    PATENT ISSUED IN THE TRANSPORT OF NO MOLECULE, L-ARGININE IN HUMANS

    MEDICAL NEWS HEADLINE:
    NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER CELL
    SITES

    January 2004

    In the treatment of cancer, there has been a great deal of interest in
    developing techniques that are capable of opening the blood-brain
    barrier to allow transport of anti-cancer agents to the brain for use
    in the entire human body.

    The blood-brain barrier is a transvascularpermeability barrier which
    is a result of the interendothelial tight junctions formed by
    cerebrovascular endothelial cells of brain capillaries and arterioles
    in brain tissues. It is known that few methodologies and techniques
    allow transport of anti-cancer agents to selectively open the
    blood-brain barrier in humans while leaving the barrier in normal
    brain tissue intact. This has been a significant issue in utilizing
    anti-tumor agents, such as nitric oxide (NO) in the treatment of human
    cancers.

    NO is known to play a significant role in anti-tumor activity in
    humans and an important role in the regulation of the blood-brain
    barrier. It is evidenced that NO can activate the calcium-activated
    potassium channel (Kca) by both cGMP-dependent and independent
    mechanisms. In order for this to occur, L-arginine, the sole NO
    molecule in the human body, must be allowed to cross the blood-brain
    barrier uninhibited so NO can be transported to specific sites for
    anti-tumor activity. This delicate mechanism has remained a mystery in
    medical science until recently.

    Following a twenty-year development period, a Patent has been issued
    to Dr. Ann de Wees Allen for an L-arginine compound that allows
    transport of L-arginine across the blood-brain barrier for production
    of growth hormone (GH) anti-aging hormone, and nitric oxide (NO).

    Dr. Allen's L-arginine formula utilizes a low glycemic base of Trutina
    Dulcem and non-competing amino acids developed under proprietary
    conditions. The specific formula prevents brain-hypoglycemia from
    blunting NO and GH produced via oral ingestion of large amounts of
    elemental L-arginine, and allows production of NO and GH without any
    side effects, thus allowing complete blood-brain barrier cross over.
    L-arginine formulas that contain sucrose, sugars, maltodextrins,
    and other sweetening agents have been shown in clinical studies to
    blunt nitric oxide (NO) and GH.

    Serious side effects related to excess NO and GH are evidenced in many
    L-arginine, nitric oxide, and growth hormone formulas currently on the
    market. When asked to comment on these "rogue products," Dr. Allen
    stated, "It's quite disturbing to see L-arginine and nitric oxide
    products popping into the market that have virtually no history of
    safe use and no science related to the development of the product."
    "You cannot simply take L-arginine and produce a valid product. It
    takes years of research."

    Dr. Ann de Wees Allen's patents have been named "Breakthrough Product
    of the Year" by Success magazine and have been featured on the front
    page of the Wall Street Journal. She is named in the Who's Who of
    Inventors and Diabetes
    Educators. Her patents, CV, and arginine research projects may be seen
    at www.arginineresearch.com

    Dr. Allen has recently licensed her L-arginine patent and technologies
    to Synergy Worldwide, a Nature's Sunshine corporation.

    Look at this site and check out the products.
    http://www.teamoneww.com/freeme
    Email me with fro this site and I will connect you to a live call with
    Dr. Allen.

    end report

    Designed by: DC Multimedia Design
     
    Tags:


Loading...